Aman Chauhan, MD, MBBS
Associate Professor
Medicine
School of Medicine

Publications (69)

Top publication keywords:
Pancreatic NeoplasmsRehydration SolutionsOncolytic VirotherapySmall Cell Lung CarcinomaOncolytic VirusesStomach NeoplasmsCarcinoma, NeuroendocrineNeuroendocrine TumorsReceptors, PeptideReceptors, Cell SurfaceNeoplasms, Unknown PrimaryTerminology as TopicIntestinal NeoplasmsEndpoint DeterminationRadiopharmaceuticals

• Neuroendocrine Tumors Have Outgrown the Orphan-Disease Framework: Building an Evidence Base for a Changing Field.
  Cancers 2026 Chauhan A, Del Rivero J
• Multi-center Phase 1 study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388).
  Clinical cancer research : an official journal of the American Association for Cancer Research 2026 Chauhan A, Weiss HL, Kunos C, Jayswal R, Konda B, Soares HP, Li D, Halfdanarson TR, Mulcahy MF, Jacene HA, Khurana A, Modak R, Yan D, Beumer JH, Christner SM, Wu PI, Das B, Rubinstein LV, Gore SD, Ivy…
• Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2026 Nonnekens J, Byers LA, Chauhan A, George DJ, Hicks RJ, Weber WA
• The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate Cancer, and Beyond.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2026 Chauhan A, Hendifar AE, El-Haddad G, Soares HP, Herrmann K
• Tarlatamab in Previously Treated Small Cell Lung Cancer: A Real-World Experience in a Predominantly Hispanic Population with CNS Metastases.
  Cancers 2026 Sucre S, Jani C, Morgenstern-Kaplan D, Nelsy Z, Modak R, Edwards K, Rose B, Malik S, Rowley K, Rauf A, Lopes G, Rodriguez E, Chauhan A

Show all (64 more) Hide

• Enhancing triapine treatment: strategies for dose optimization and methemoglobin level mitigation.
  Cancer chemotherapy and pharmacology 2026 Lee H, Dunn A, Taylor SE, Chauhan A, Ivy SP, Gobburu J, Beumer JH
• A case report of acute carcinoid heart failure during lutetium-177 dotatate-triapine treatment for well-differentiated neuroendocrine tumors.
  Frontiers in oncology 2026 Chauhan A, Kohn EC, Ivy SP, Kolesar JM, Modak R, Arnold S, Anthony L, Carson WE, Shelman NR, Kunos CA
• Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315).
  The oncologist 2026 Mandl A, Chen R, Das S, Strosberg JR, Kasi A, Konda B, Li D, Burns TF, Chauhan A, Ciombor KK, Dayyani F, Dorff T, Ohr JP, Patel BB, Sukrithan V, Soares HP, Chen K, Liu SV, Tesfaye AA, Carducci MA, …
• The genomic, transcriptomic, and immunologic landscape of TEM8 (ANTXR1) in neuroendocrine neoplasms (NENs) including small-cell lung cancer (SCLC).
  Cancer treatment and research communications 2026 Kareff SA, Krause H, Elliott A, Samec T, Lopes G, Hosein PJ, Jani CT, Lou E, Soares H, Magistri M, Sumarriva D, Oberley M, Chauhan A
• PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
  Endocrine-related cancer 2026 Corbett V, Gupta G, Chauhan A
• Treating Pediatric Oncology Patients: The Emerging Role of Radioligand Therapy.
  Cancers 2025 Laetsch TW, States LJ, Lazow MA, Chauhan A
• Dethroning of Neuroendocrine Tumor as an Orphan Disease: US Incidence, Prevalence, and Survival in the 21st Century.
  Cancers 2025 Yu Q, Cao F, Hosein P, Huang B, Pinheiro PS, Wang Y, Del Rivero J, Lopes G, Chauhan A
• Sequencing Choices and Real-World Clinical Management in Advanced Grade 2/3 GEP-NET Treatment: The Emerging Role of PRRT.
  Cancers 2025 Chauhan A, Halfdanarson TR, Vijayvergia N
• Evolving strategies in the management of non-small cell lung cancer brain metastases: insights from the C-Brain trial.
  Chinese clinical oncology 2025 Jani CT, Lopes G, Hao Z, Chauhan A
• Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
  JCO oncology practice 2025 Perez K, Del Rivero J, Kennedy EB, Basu S, Chauhan A, Connolly HM, Dasari AN, Gangi A, Clarke CN, Hallet J, Howe JR, Grady E, Ivanidze J, Mittra ES, White SB, Raj NP, Vijayvergia N, Lewis MA, Chan JA,…
• Prospects for radioimmunotherapy panaceas in gynecologic oncology.
  Cancer 2025 Kunos CA, Chauhan A
• Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892).
  Cancer chemotherapy and pharmacology 2024 Taylor SE, Behr S, Cooper KL, Mahdi H, Fabian D, Gallion H, Ueland F, Vargo J, Orr B, Girda E, Courtney-Brooks M, Olawaiye AB, Randall LM, Richardson DL, Sullivan SA, Huang M, Christner SM, Beriwal S,…
• Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).
  Journal for immunotherapy of cancer 2024 Vaishampayan UN, Muzaffar J, Winer I, Rosen SD, Hoimes CJ, Chauhan A, Spreafico A, Lewis KD, Bruno DS, Dumas O, McDermott DF, Strauss JF, Chu QS, Gilbert L, Chaudhry A, Calvo E, Dalal R, Boni V, …
• Triplet regimen with camrelizumab plus apatinib in combination with hepatic artery infusion chemotherapy (HAIC): a new treatment paradigm for select patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma?
  Chinese clinical oncology 2024 Gupta G, Patel R, Akce M, Chauhan A
• A neuroendocrine biomarker revolution from monoanalyte to multianalyte biomarkers in non-functioning gastro-entero-pancreatic neuroendocrine neoplasms.
  Critical reviews in oncology/hematology 2024 Hoff CO, Manzi J, Ferreira R, Chauhan A, Housein P, Merchant N, Livingstone A, Vianna R, Abreu P
• AJCC Cancer Staging System Version 9: Practice-Informing Updates for Gastroenteropancreatic Neuroendocrine Tumors.
  Annals of surgical oncology 2024 Chan K, Chauhan A, Shi C
• Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor.
  Cancer letters 2024 Chow Z, Johnson J, Chauhan A, Jeong JC, Castle JT, Izumi T, Weiss H, Townsend CM, Schrader J, Anthony L, Yang ES, Evers BM, Rychahou P
• Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors.
  CA: a cancer journal for clinicians 2024 Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, …
• Leveraging Programmatic Collaboration for a Radiopharmaceutical Clinic.
  Cancers 2024 Kunos CA, Martin ME, Georgiou MF, Kuker RA, Chauhan A
• Development and validation of a chromatin regulator signature for predicting prognosis hepatocellular carcinoma patient.
  Journal of gastrointestinal oncology 2024 Mao J, Song F, Zhang Y, Li Y, Inchingolo R, Chauhan A, Midorikawa Y, Chen Z, Tang W
• Role of CDK4/6 inhibitors in targeting Rb proficient small cell lung cancer.
  Translational lung cancer research 2024 Corbett V, Sen T, Chauhan A
• Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial.
  JAMA oncology 2023 Takahashi N, Hao Z, Villaruz LC, Zhang J, Ruiz J, Petty WJ, Mamdani H, Riess JW, Nieva J, Pachecho JM, Fuld AD, Shum E, Chauhan A, Nichols S, Shimellis H, McGlone J, Sciuto L, Pinkiert D, Graham C, …
• TEM8 in Oncogenesis: Protein Biology, Pre-Clinical Agents, and Clinical Rationale.
  Cells 2023 Kareff SA, Corbett V, Hallenbeck P, Chauhan A
• Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC…
• Review of practice informing data and current state of NCCN consensus guidelines in hepatobiliary cancers.
  Hepatobiliary surgery and nutrition 2023 Corbett V, Li D, Chauhan A
• Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.
  Journal of the National Cancer Institute 2023 Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, …
• Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors.
  The oncologist 2023 Cheng Y, Anthony L, Delcher C, Moga DC, Chauhan A, Huang B, Adams V
• Pulmonary large cell neuroendocrine carcinoma (LCNEC): a population-based study addressing recent molecular-genetic advances and emerging therapeutic approaches.
  Clinical and experimental medicine 2023 Khan J, Yasinzai AQK, Matosz S, Khan M, Heneidi S, Mesa H, Chauhan A, Del Rivero J, Karim NA, Ullah A
• Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review.
  Cancers 2022 Chauhan A, Del Rivero J, Ramirez RA, Soares HP, Li D
• Real-World Clinical and Patient-Reported Outcomes from the Longitudinal Telotristat Ethyl Treatment Registry of Patients with Neuroendocrine Tumors.
  Cancer management and research 2022 Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A
• Pediatric Neuroendocrine Neoplasms: Rare Malignancies with Incredible Variability.
  Cancers 2022 Castle JT, Levy BE, Chauhan A
• Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics.
  Frontiers in molecular biosciences 2022 Corbett V, Hallenbeck P, Rychahou P, Chauhan A
• Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review.
  Pharmaceutics 2022 Priyadarshini S, Allison DB, Chauhan A
• An Update on the Management of Mixed Neuroendocrine-Non-neuroendocrine Neoplasms (MiNEN).
  Current treatment options in oncology 2022 Jacob A, Raj R, Allison DB, Soares HP, Chauhan A
• hPG80 (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors.
  Cancers 2022 Chauhan A, Prieur A, Kolesar J, Arnold S, Payen L, Mahi Y, Vire B, Sands M, Evers BM, Joubert D, Anthony L
• External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy.
  JAMA network open 2022 Das S, Chauhan A, Du L, Thomas KE, Jacob A, Schad A, Jain S, Jessop A, Shah C, Eisner D, Cardin DB, Ciombor KK, Goff LW, Bradshaw M, Delbeke D, Sandler M, Ramirez RA, Berlin J
• Management of Large Cell Neuroendocrine Carcinoma.
  Frontiers in oncology 2021 Corbett V, Arnold S, Anthony L, Chauhan A
• Adjuvant therapy for lung neuroendocrine neoplasms.
  World journal of clinical oncology 2021 Ramirez RA, Thomas K, Jacob A, Lin K, Bren-Mattison Y, Chauhan A
• Prevalence of TP-53/Rb-1 Co-Mutation in Large Cell Neuroendocrine Carcinoma.
  Frontiers in oncology 2021 Saghaeiannejad Esfahani H, Vela CM, Chauhan A
• Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients?
  BMC cancer 2021 Chauhan A, Das S, Miller R, Luque L, Cheuvront SN, Cloud J, Tarter Z, Siddiqui F, Ramirez RA, Anthony L
• PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors.
  Cells 2021 Chow Z, Johnson J, Chauhan A, Izumi T, Cavnar M, Weiss H, Townsend CM, Anthony L, Wasilchenko C, Melton ML, Schrader J, Evers BM, Rychahou P
• Radiopharmaceutical Validation for Clinical Use.
  Frontiers in oncology 2021 Kunos CA, Howells R, Chauhan A, Myint ZW, Bernard ME, El Khouli R, Capala J
• Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry.
  Cancer medicine 2021 Jacob A, Wu J, Kolesar J, Durbin E, Mathew A, Arnold S, Chauhan A
• Gynecologic large cell neuroendocrine carcinoma: A review.
  Rare tumors 2020 Burkeen G, Chauhan A, Agrawal R, Raiker R, Kolesar J, Anthony L, Evers BM, Arnold S
• 68Ga-DOTATATE PET/CT: The Optimum Standardized Uptake Value (SUV) Internal Reference.
  Academic radiology 2020 Ragab A, Wu J, Ding X, Clark A, Mischen B, Chauhan A, Oates ME, Anthony L, El Khouli R
• Clinical Application of Oncolytic Viruses: A Systematic Review.
  International journal of molecular sciences 2020 Cook M, Chauhan A
• Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: A retrospective analysis in neuroendocrine tumor patients.
  Oncotarget 2020 Chauhan A, El-Khouli R, Waits T, Agrawal R, Siddiqui F, Tarter Z, Horn M, Weiss H, Oates E, Evers BM, Anthony L
• Prognostic and predictive factors associated with ipilimumab-related adverse events: a retrospective analysis of 11 NCI-sponsored phase I clinical trials.
  Oncotarget 2020 Chauhan A, Kabir T, Wu J, Wei J, Cook M, Kunos CA
• Immunotherapy for Medulloblastoma: Current Perspectives.
  ImmunoTargets and therapy 2020 Kabir TF, Kunos CA, Villano JL, Chauhan A
• Neuroendocrine Tumors-Less Well Known, Often Misunderstood, and Rapidly Growing in Incidence.
  JAMA oncology 2020 Chauhan A, Kohn E, Del Rivero J
• Biliary tract large cell neuroendocrine carcinoma: current evidence.
  Orphanet journal of rare diseases 2019 Raiker R, Chauhan A, Hasanein H, Burkeen G, Horn M, Veedu J, Vela C, Arnold S, Kolesar J, Anthony L, Evers BM, Cavnar M
• Two-stage phase II survival trial design.
  Pharmaceutical statistics 2019 Wu J, Chen L, Wei J, Weiss H, Chauhan A
• Does the addition of adjuvant intraoperative tumor bed chemotherapy during midgut neuroendocrine tumor debulking procedures benefit patients?
  Journal of gastrointestinal oncology 2019 Wang YZ, Chauhan A, Ramirez RA, Beyer DT, Stevens MA, Woltering EA, Boudreaux JP, Anthony L
• Neuroendocrine Tumors in Pediatrics.
  Global pediatric health 2019 Farooqui ZA, Chauhan A
• Integrating a 92-Gene Expression Analysis for the Management of Neuroendocrine Tumors of Unknown Primary
  Asian Pacific journal of cancer prevention : APJCP 2019 Chauhan A, Farooqui Z, Silva SR, Murray A, Hodges KB, Yu Q, Myint ZW, Raajesekar AK, Weiss H, Arnold S, Evers BM, Anthony L
• Can a High-grade Neuroendocrine Carcinoma be Functional?
  The American journal of the medical sciences 2018 Graham C, Chauhan A, Anthony L
• Management of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: Review and a Single Center Experience.
  Lung 2018 Myint ZW, McCormick J, Chauhan A, Behrens E, Anthony LB
• Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary.
  Journal of oncology 2018 Chauhan A, Farooqui Z, Murray LA, Weiss HL, War Myint Z, Raajasekar AKA, Evers BM, Arnold S, Anthony L
• Global burden of neuroendocrine tumors and changing incidence in Kentucky.
  Oncotarget 2018 Chauhan A, Yu Q, Ray N, Farooqui Z, Huang B, Durbin EB, Tucker T, Evers M, Arnold S, Anthony LB
• Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status.
  Oncotarget 2018 Chauhan A, Arnold SM, Kolesar J, Thomas HE, Evers M, Anthony L
• Immune Checkpoint Inhibitors in Pediatric Solid Tumors: Status in 2018.
  Ochsner journal 2018 Kabir TF, Chauhan A, Anthony L, Hildebrandt GC
• Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature.
  Oncotarget 2017 Chauhan A, Horn M, Magee G, Hodges K, Evers M, Arnold S, Anthony L
• Management of pulmonary neuroendocrine tumors.
  Reviews in endocrine & metabolic disorders 2017 Ramirez RA, Chauhan A, Gimenez J, Thomas KEH, Kokodis I, Voros BA
• The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
  The oncologist 2016 Ramirez RA, Beyer DT, Chauhan A, Boudreaux JP, Wang YZ, Woltering EA